Irinotecan-d10 (hydrochloride)

Irinotecan-d10 (hydrochloride) is the deuterium labeled Irinotecan. Irinotecan ((+) -Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex[1][2].

Product Specifications

CAS Number

[718612-62-5]

UNSPSC

12352005

Hazard Statement

H302, H361

Target

Autophagy; Isotope-Labeled Compounds; Topoisomerase

Type

Isotope-Labeled Compounds

Related Pathways

Autophagy; Cell Cycle/DNA Damage; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

99.76

Solubility

10 mM in DMSO|DMSO : 25mg/mL (ultrasonic)

Smiles

C(C)C1=C2C(C=3N(C2)C(=O)C4=C(C3)[C@](CC)(O)C(=O)OC4)=NC=5C1=CC(OC(=O)N6CCC(CC6)N7C(C(C(C(C7([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H])=CC5.Cl

Molecular Formula

C33H29D10ClN4O6

Molecular Weight

633.20

Precautions

H302, H361

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56 (3) :219-26.|[3]Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49 (4) :329-35. Epub 2002 Jan 30.|[4]Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53 (3) :261-6. Epub 2003 Dec 5.|[5]Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8 (1) :116.|[6]Huang MY, et al. Chemotherapeutic agent CPT-11 eliminates peritoneal resident macrophages by inducing apoptosis. Apoptosis. 2016 Feb;21 (2) :130-42.